AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

DIACEUTICS PLC

Director's Dealing May 23, 2024

7596_dirs_2024-05-23_e7d15054-3701-43f3-b795-c9b89e66803b.html

Director's Dealing

Open in Viewer

Opens in native device viewer

National Storage Mechanism | Additional information

RNS Number : 5550P

Diaceutics PLC

23 May 2024

Director / PDMR Shareholding - NED Purchase of Shares

Belfast and London, 23 May 2024 - Diaceutics PLC (AIM: DXRX) ("Diaceutics" or the "Company"), a leading technology and solutions provider to the pharma and biotech industry announces that on 22 May 2024, Graham Paterson, a Non-Executive Director of Diaceutics, purchased 39,934 ordinary shares of £0.002 each in the Company ("Ordinary Shares") at a price of £1.2889 per Ordinary Share. As a result of the purchase, Graham Paterson's shareholding in Diaceutics is 73,498 Ordinary Shares representing approximately 0.09% of the Company's issued share capital.

Enquiries:  

Diaceutics PLC
Ryan Keeling, Chief Executive Officer  

Nick Roberts, Chief Financial Officer
Tel: +44 (0)28 9040 6500

[email protected]
Stifel Nicolaus Europe Limited (Nomad & Broker) Tel: +44 (0)20 7710 7600
Ben Maddison
Nick Harland
Kate Hanshaw
Alma Strategic Communications Tel: +44(0)20 3405 0205
Caroline Forde [email protected]

About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome.

We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostics Network®.

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
1 Details of the person discharging managerial responsibilities/person closely associated
a. Name Graham Paterson
2 Reason for notification
a. Position/Status Non-Executive Director
b. Initial notification/

Amendment
Initial
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a. Name Diaceutics PLC
b. LEI 213800VEWQBB39ZB8J81
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a. Description of the financial instrument, type of instrument



Identification Code
Ordinary shares of £0.002 each

ISIN:  GB00BJQTGV64
b. Nature of the transaction Purchase
c. Price(s) and volume(s) Share purchase:
Price(s) Volume(s)
£1.2889 39,934
d. Date of the transaction 22 May 2024
e. Place of the transaction AIM Market of the London Stock Exchange

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHQKBBNDBKBOPB

Talk to a Data Expert

Have a question? We'll get back to you promptly.